Vesalius has provided $4.7m to Forendo Pharma, whose existing shareholders also include Karolinska Development, Novartis, Novo and Merck Group.
Forendo Pharma, a Finland-based gynaecological therapy based on research from University of Turku, secured €4m ($4.7m) in funding on Wednesday from Vesalius Biocapital III Partners, a growth-stage vehicle managed by VC firm Vesalius Biocapital Partners.
Forendo Pharma focuses on the development of therapies for disorders affecting the organs in the female pelvic and abdominal regions.
The spinout’s lead development candidate, For 6219, targets a long-term condition called endometriosis where internal womb tissue has proliferated into external areas such as the ovaries and fallopian tubes. The asset is currently undergoing a phase 1a trial.
Forendo has also launched pre-clinical discovery efforts for a program that would target a broader range of gynaecological conditions and has completed phase 2 studies on an oestrogen receptor modulator, fispemifene, for male urological conditions.
Forendo was spun out from Hormos Medical, a subsidiary of biopharmaceutical firm QuatRx Pharmaceuticals, in 2013 and is partially based on research…
